Onyx Pharmaceuticals Announces December 2009 Investor Events
26 November 2009 - 8:00AM
PR Newswire (US)
American Society of Hematology (ASH) Briefing and Analyst Briefing
EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx
Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that the
company will host two investor events in December: ASH Briefing
December 7, 2009 - 9:00 a.m. CT/10:00 a.m. ET Principal
investigators will discuss data presentations surrounding
carfilzomib in relapsed and/or refractory multiple myeloma, as
featured at the 51st American Society of Hematology (ASH) Annual
Meeting and Exposition in New Orleans, LA. The teleconference will
begin at 9:00 a.m. CT/10:00 a.m. ET on December 7, 2009. The live
webcast will be available at:
http://www.onyx-pharm.com/view.cfm/32/Event-Calendar or by dialing
847-413-3362 and using the passcode 25914947. A replay of the
presentation will be available on the Onyx website or by dialing
630-652-3044 and using the passcode 25914947 later in the day. The
replay will be available on the Onyx website through January 7,
2010. Analyst Briefing on Development Program December 17, 2009 -
8:30 a.m. ET Onyx management will host an overview of its
development program on December 17, 2009 at 8:30 a.m. ET. The
program will feature presentations on multiple tumor types by
external clinical investigators and members of management.
Subsequent to the prepared remarks, the company will conduct a
Q&A session with panelists and members of the management team.
Further details regarding Analyst Day, including webcast
information, will be announced closer to the event. About Onyx
Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. is a
biopharmaceutical company committed to improving the lives of
people with cancer. The company, in collaboration with Bayer
HealthCare Pharmaceuticals, Inc., is developing and marketing
Nexavar® (sorafenib) tablets a small molecule drug that is
currently approved for the treatment of liver cancer and advanced
kidney cancer. Additionally, Nexavar is being investigated in
several ongoing trials in a variety of tumor types. Beyond Nexavar,
Onyx has established a development pipeline of anticancer compounds
at various stages of clinical testing, including carfilzomib, a
next-generation proteasome inhibitor, that is currently being
evaluated in multiple clinical trials for the treatment of patients
with relapsed or relapsed/refractory multiple myeloma and solid
tumors. ONX 0801 is a targeted alpha-folate inhibitor currently in
Phase 1 testing. For more information about Onyx, visit the
company's website at http://www.onyx-pharm.com/. Nexavar®
(sorafenib) tablets is a registered trademark of Bayer HealthCare
Pharmaceuticals. DATASOURCE: Onyx Pharmaceuticals, Inc. CONTACT:
Alex Santos of Onyx Pharmaceuticals, Inc., +1-510-597-6504 Web
Site: http://www.onyx-pharm.com/
Copyright